Celsee LLC

– The announcement follows the company's groundbreaking clinical data presented at the American College of Rheumatology annual meeting HAYWARD, Calif., Dec. 19, 2023 /PRNewswire/ -- Aqtual, a precision medicine company with a novel cfDNA platform to aid in treatment decisions for chronic diseases and cancers through a simple blood test, announced today that Gregg C. Fergus has joined as a member of its board of directors. Gregg brings over 30 years of corporate, entrepreneurial, and venture capital experience working with category-defining companies in life sciences. Continue Reading Aqtual has named Gregg C. Fergus as a member of its board of directors. Gregg was CEO of 4Catalyzer, where he launched groundbreaking companies, including Butterfly Network, Hyperfine, Quantum-Si, and AI Therapeutics. Prior to 4Catalyzer, Gregg was president and COO of Ion Torrent, which sold to Life Technologies and is now a division of Thermo Scientific. Gregg also held senior leadership roles at Baird Venture Partners and Affymetrix. He has founded or sat on the board of numerous companies and non-profit organizations, including Cernostics, Verda Bio, Celsee, iGenomX, Healthy Minds Innovations, and Special Olympics Wisconsin. Gregg currently serves as executive chairman of the board at Ascertain. "I did a years-long exhaustive search looking for the best-in-class cell-free DNA technology, and Aqtual's platform is set to revolutionize the liquid biopsy space," said Fergus. "Aqtual is unique in that its platform provides an unbiased and comprehensive view of gene expression without the need for RNA, generating an unprecedented amount of clinically useful information from a single blood test. I am thrilled to join the board and support Aqtual's vision." Gregg joins a board of industry veterans in precision medicine and healthcare, including Aqtual co-founder and CEO Diana Abdeuva, Ph.D., and co-founder and CTO Richard Rava, Ph.D., Jenny Rooke, Ph.D., founder and managing partner of Genoa Ventures, Lawrence Barclay, managing partner of Manta Ray, and PR Yu, Ph.D., managing partner of Yu Galaxy. Last month, Aqtual presented research at the American College of Rheumatology's annual Convergence meeting, demonstrating that synovial transcriptomic signals were detected in blood plasma using Aqtual's DNA capture platform. The platform was able to comprehensively analyze and characterize molecular signals in rheumatoid arthritis (RA) and differentiate those signals from other inflammatory conditions. The company's proof-of-concept clinical trial, PRIMA-102, will close enrollment in early 2024, with its RA blood test, a classifier capable of predicting effective drug classes for patients, expected to launch in early 2025. "Our platform is the first to deliver a comprehensive view of gene expression through a blood test, which provides us with unlimited clinical utility," said Diana Abdueva, Ph.D. and CEO of Aqtual. "With Gregg's deep commercial and operational experience, we can accelerate our vision of streamlining therapeutic decisions for patients across the globe." About Aqtual, Inc. Aqtual, Inc. is a precision medicine company developing products for chronic disease management and oncology utilizing a novel cell-free DNA-based platform. Aqtual's proprietary platform evaluates protein regulation, epigenetics, and transcriptomics solely using cell-free DNA fragments found in blood. The platform yields efficient and robust real-time analysis of disease and treatment while overcoming the limitations of standard cell-free DNA methodologies. SOURCE Aqtual

Life sciences tools veteran brings decades of experience leading successful teams, commercializing industry-defining technology platforms, and scaling global organizations MONHEIM AM RHEIN, Germany--(BUSINESS WIRE)-- Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences’ previous CEO, Jason Gammack, will be leaving the company. Mr. Stark brings more than 20 years of experience commercializing early-stage technologies, scaling organizations, and navigating capital markets for some of the most innovative life sciences companies. Most recently, Mr. Stark was Chief Executive Officer of Quantum-Si (NASDAQ: QSI), a next-generation, single-molecule protein sequencing platform company. Prior to that, he served as CEO of Celsee, a novel single-cell genomics platform company that was acquired by Bio-Rad (NYSE: BIO) in 2020. Earlier in his career, Mr. Stark held senior leadership positions at Life Technologies (acquired by Thermo Fisher Scientific, NYSE:TMO), Pacific Biosciences (NASDAQ: PACB), and Affymetrix (acquired by Thermo Fisher Scientific). “The Board is excited to welcome John to Resolve Biosciences to lead our next chapter of growth and success,” said Peer M. Schatz, co-founder and Chairman of the Board. “John brings an impressive track record of execution, operational excellence, and successful team building to drive innovation. Throughout his career, John has consistently delivered high-growth results for numerous industry-defining platforms. We look forward to working with him on our quest to shape the future of spatial biology and realize the massive opportunities and vast applications in science and medicine.” Mr. Schatz added, “We deeply appreciate Jason Gammack for his contributions and leadership of the company as former CEO, including shepherding the company through the COVID-19 pandemic and initial launch of our commercial platform and service offering.” “I am honored to join Resolve Biosciences as its next Chief Executive Officer,” said Mr. Stark. “It is rare to find an opportunity like this to lead a growing company with a transformative technology and a brilliant and passionate team. I’m looking forward to empowering our global partners and customers with the ability to realize the full potential of our Molecular Cartography technology. We are dedicated to delivering best-in-class products that will enable the understanding of the molecular causes of disease and associated immune response.” About Resolve Biosciences Resolve Biosciences is applying the power of Molecular Cartography™ technology to enable scientists to gain new insights based on the highest-resolution view of spatial biology. The complete system features the company's proprietary, highly multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a fully automated workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity to help scientists detect individual transcripts and rare signals to interpret fundamental biology and to rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, infectious disease, and agriculture. Resolve Biosciences is privately held and based in Monheim am Rhein, Germany, with a North American facility and laboratory in San Jose, Calif. For additional information, visit . Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

High Need for Rapid Virus Detection Pushing PCR Reagents Market Forward, States Fact.MR “Commercial use of PCR reagents as a molecular diagnostic tool and in forensic analysis will drive market growth over the coming years,” says a Fact.MR analyst. Fact.MR, a market research and competitive intelligence provider: The global PCR reagents market is estimated at US$ 1.25 billion in 2022. During 2017-2021, the market registered remarkable annual growth of 35.7%. One of the factors driving demand for PCR reagents is their increased use in the field of epigenetic research, along with rising investments in the life sciences industry. Use of PCR reagents is significantly impacted by the high demand for rapid testing in molecular diagnostics and point-of-care kits. Advancements in Next Generation Sequencing (NGS) are further accelerating the use of PCR in molecular diagnostics and research. Adoption of novel biotechnology and improvements in healthcare infrastructure are expanding the applications of Polymerase Chain Reaction (PCR) as a diagnostic tool. Rise in investments in the life sciences sector and % GDP healthcare spending has fuelled the research at a genomic level. The molecular insights of the human body and fellow organisms are opening up broad markets to be explored by PCR reagents. For more insights into the Market, Get A Sample of this Report! Key Takeaways from Market Study The global PCR reagents market is projected to expand at an impressive CAGR of 6.4% and be valued at US$ 2.32 billion by 2032. Under the application segment, virus detection dominates the market and is valued at US$ 617.8 million in 2022. Europe dominated the market with 27.7% market share in 2021. Primary reagents occupy 91.6% of the global PCR reagents market in 2022 and this dominance is expected to continue throughout the forecast period. Together, South Asia & ASEAN and Oceania are likely to represent 16.6% market share in 2022. Market Development Manufacturers in the field are focusing on robust research and development to attain the high accuracy and compatibility of reagents. The hit of the pandemic has also introduced numerous global leaders as well as local manufacturers into the market. Global leaders are collaborating with local manufacturers to boost their consumer penetration and production capacity. Innovating PCR as a diagnostic tool against existing slow pathogen detection techniques has been a popular organic growth approach in the market. For Comprehensive Insights Ask An Analyst Here Competitive Landscape Prominent PCR reagent manufacturers are Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Thermofishers, Biotium, MiRXES Pte Ltd, GeneDireX, Inc., Norgen Biotek Corp, Takara Holdings Inc., Qiagen, PCR Biosystems, Tonbo Biosciences, Quantabio, Kaneka Eurogentec S.A, Promega Corporation, InBios International, Abbott, Siemens Healthcare GmbH, bioMérieux SA, and F. Hoffmann-La Roche AG. Sales of PCR products such as PCR reagents have been further boosted by the availability of customized PCR reagents that guarantee the effectiveness and accuracy of tests, provided by a few key companies such as Bio-Rad and PCR Bio Systems. IsoFast Bst Polymerase reagents from PCR Biosystems were launched in March 2021, supporting sensitive, robust, and quick amplification of RNA and DNA. This allows for quicker testing methods. Bio-Rad acquired Celsee, Inc., a single-cell analysis solutions provider, in April 2020. This acquisition will expand Bio-rad’s reach in the rapidly growing world of precision medicine and molecular diagnosis. Segmentation of PCR Reagents Industry Research PCR Reagents Market by Reagent Type: Primary Primers Polymerase Pol Specific Buffer Deoxynucleotides Template Sterile Water Secondary Magnesium Salt Potassium Salt Dimethyl sulfoxide (DMSO) Bovine Serum Albumin (BSA) Form amide Betaine PCR Reagents Market by Form: Liquid PCR Reagents Powder PCR Reagents PCR Reagents Market by Packaging: Master Mixes Singleplex Multiplex Kits PCR Reagents Market by Application: Conventional Amplification Genotyping Mutation Analysis SNP Loci Amplification Virus Detection STR and Microsatellite Analysis Gene Expression Analysis Molecular Cloning RNA Detection Others PCR Reagents Market by Region: North America Latin America Europe East Asia South Asia & ASEAN Oceania MEA Get Customization on this Report for Specific Research Solutions More Valuable Insights on Offer Fact.MR, in its new offering, presents an unbiased analysis of the global PCR Reagents Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032. The study reveals essential insights on the basis of reagent type (primary, secondary), form (liquid, powder), packaging (master mixes, kits), and application (conventional amplification, genotyping, mutation analysis, SNP loci amplification, virus detection, STR and microsatellite analysis, gene expression analysis, molecular cloning, RNA detection, others), across major regions of the world (North America, Latin America, Europe, East Asia, South Asia & Oceania, and the Middle East & Africa). Fact.MR’s Domain Knowledge in Healthcare Division Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over thousand reports and 1 million-plus data points, the team has analysed the healthcare division across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Check out more studies related to Healthcare Industry, conducted by Fact.MR: No Sting Barrier Market - No Sting Barrier Market Analysis, By Product Type (Sprays, Foams, Wipes, Creams), By Buyer Category (Individuals, Clinical Professionals/Clinics, Hospitals), By Use Case (Device Securement, Infusion Therapy, Skin Care, Wound Care), By Sales Channel (Online, Offline) - Global Market Insights 2022 to 2032 Diabetes Management Software Market - Diabetes Management Software Market By Device (Wearable Devices, Handheld Devices), By Application (Diabetes & Blood Glucose Tracking, Obesity & Diet Management), By End User (Self/Home Healthcare, Hospitals & Specialty Diabetes Clinics, Academic & Research Institutes) & Region - Global Market Insights 2022 to 2032 Nucleic Acid Extraction System Market - Nucleic Acid Extraction System Market By Product (DNA Extraction, RNA Extraction, Protein Extraction), By Application (Hospitals & Diagnostic Centers, Life Science, Pharmaceuticals, Academic, Medical & Clinical Research) & Region - Global Market Insights 2022 to 2032 Tissue Processor Equipment Market - Tissue Processor Equipment Market By Component (Fixative, Ethanol) By Industry (Laboratories, Hospitals, Pharmaceutical Companies) - Global Market Insights 2021 to 2031 Lab Workflow Solutions Market - Lab Workflow Solutions Market Analysis, By Type (Data Integration Solutions, Real-time Communication Solutions, Workflow Automation Solutions, Care Collaboration Solutions, Enterprise Reporting & Analytics Solutions) By End Use (Hospitals, Long-term Care Facilities, Ambulatory Care Centers), - Global Market Insights 2022 to 2032 Epigenetics Market - Epigenetics Market Analysis, By Product (Kits, Reagents, Enzymes, Bioinformatics Tools, Instruments & Consumables) By Application (Immunology, Oncology, Cardiovascular Diseases, Metabolic Diseases, Non-Oncology) By Technology (DNA Methylation, Histone Methylation, Histone Acetylation, MicroRNA Modification, Chromatic Structures) - Global Market Insights 2022 to 2032 Vertebroplasty and Kyphoplasty Needles Market - Vertebroplasty and Kyphoplasty Needles Market by Procedure (Kyphoplasty Procedures, Vertebroplasty Procedures), by End User (Hospitals, Ambulatory Surgical Centers) & Region Forecast till 2032 MRI Safe Implantable Defibrillator Devices Market - MRI Safe Implantable Defibrillator Devices Market By Product (Single Chamber Defibrillators, Dual Chamber Defibrillators), By Modality (MR Conditional Defibrillators, MR Safe Defibrillators), By End Use (Hospitals, Ambulatory Surgical Centers), & By Region - Global Forecast 2022-2032 Europe Patient Positioning System Market - Europe Patient Positioning System Market Analysis, By Product (Patient Positioning Tables, Surgical Tables, Radiolucent Imaging Tables, Examination Tables, Patient Positioning Accessories), By Application (Surgeries, Disease Diagnosis & Imaging, Cancer Therapy), By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres) - European Market Insights 2022 to 2032 Intrapartum Monitoring Devices Market - Intrapartum Monitoring Devices Market Analysis by Product (Monitors, Electrodes) and Region Forecast- 2022-2032 About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 Email: sales@factmr.com Tel: +1 (628) 251-158